PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-26.96%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-36.13%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-206.50%
Negative EBIT growth while CVE is at 16.97%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-206.50%
Negative operating income growth while CVE is at 16.97%. Joel Greenblatt would press for urgent turnaround measures.
38.07%
Net income growth under 50% of CVE's 81.59%. Michael Burry would suspect the firm is falling well behind a key competitor.
38.02%
EPS growth under 50% of CVE's 81.82%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
38.57%
Diluted EPS growth under 50% of CVE's 81.82%. Michael Burry would worry about an eroding competitive position or excessive dilution.
-0.10%
Share reduction while CVE is at 0.61%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
0.81%
Diluted share change of 0.81% while CVE is zero. Bruce Berkowitz might see a minor difference that could widen over time.
-66.63%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
-64.96%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-220.24%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
-81.09%
Both companies have negative long-term revenue/share growth. Martin Whitman would question if the entire market or product set is shrinking.
-60.51%
Both face negative 5Y revenue/share CAGR. Martin Whitman would suspect macro headwinds or obsolete product offerings across the niche.
-38.33%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
-91.99%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-78.32%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-59.71%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-130.15%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-524.79%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
23.73%
Positive short-term CAGR while CVE is negative. John Neff would see a clear advantage in near-term profit trajectory.
-61.08%
Negative equity/share CAGR over 10 years while CVE stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-71.55%
Negative 5Y equity/share growth while CVE is at 30.16%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
1.55%
Below 50% of CVE's 10.50%. Michael Burry suspects a serious short-term disadvantage in building book value.
-76.18%
Cut dividends over 10 years while CVE stands at 0.00%. Joel Greenblatt suspects a weaker ability to return capital vs. the competitor.
-92.27%
Both lowered dividends mid-term. Martin Whitman might suspect broad sector constraints or strategic shifts from dividends.
-92.33%
Both firms reduced dividends recently. Martin Whitman suspects broader macro or industry issues forcing cost and payout cuts.
-36.84%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
-100.00%
Inventory is declining while CVE stands at 5.93%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-2.82%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-10.64%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
1.00%
We have some new debt while CVE reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
No Data
No Data available this quarter, please select a different quarter.
-0.85%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.